<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905277</url>
  </required_header>
  <id_info>
    <org_study_id>18-005725</org_study_id>
    <nct_id>NCT04905277</nct_id>
  </id_info>
  <brief_title>Atenolol for the Prevention of Osteoporosis (APO)</brief_title>
  <acronym>APO</acronym>
  <official_title>Beta1-Selective Blockade for Prevention of Postmenopausal Bone Loss: A Phase 3, Multi-Center, Double-Blinded, Randomized Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sundeep Khosla, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MaineHealth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss&#xD;
      at the lower back and hip in postmenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">January 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Atenolol vs. Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome: Percent change in femur neck bone mineral density (BMD)</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Percent change in femur neck bone mineral density (BMD) by DXA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes: Percent changes in lumbar spine and total hip BMD</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Percent changes in lumbar spine and total hip BMD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will take Atenolol 50 mg daily over 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study subjects will take a placebo daily over 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol 50 MG</intervention_name>
    <description>50 mg Atenolol daily</description>
    <arm_group_label>Atenolol</arm_group_label>
    <other_name>Atenolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one placebo daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Postmenopausal women (FSH ≥ 16 IU/L) (no menses for at least one year)&#xD;
&#xD;
          -  Aged 50-75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of diabetes mellitus requiring insulin&#xD;
&#xD;
          -  Clinically significant abnormality in any of the additional screening laboratory&#xD;
             studies&#xD;
&#xD;
          -  A1c- ≥8&#xD;
&#xD;
          -  Calcium - &gt; upper limit lab value per site&#xD;
&#xD;
          -  AST- 2x upper normal limit&#xD;
&#xD;
          -  FSH- &lt; 16IU/L&#xD;
&#xD;
          -  eGFR- &lt; 45 mL/min/1.73m2 based on creatinine&#xD;
&#xD;
          -  CBC- Per PI interpretation of each patient&#xD;
&#xD;
          -  Presence of (documented clinical diagnosis of any of the following):&#xD;
&#xD;
               -  Significant liver or renal disease&#xD;
&#xD;
               -  Malignancy (including myeloma or clinical diagnosis of MGUS)&#xD;
&#xD;
               -  Malabsorption (as defined by clinical diagnosis)&#xD;
&#xD;
               -  Hypoparathyroidism (as defined by clinical diagnosis)&#xD;
&#xD;
               -  Hyperparathyroidism (as defined by clinical diagnosis)&#xD;
&#xD;
               -  Acromegaly&#xD;
&#xD;
               -  Cushing syndrome&#xD;
&#xD;
               -  Hypopituitarism&#xD;
&#xD;
               -  Severe chronic obstructive pulmonary disease&#xD;
&#xD;
               -  Pheochromocytoma&#xD;
&#xD;
               -  History of cardiac failure&#xD;
&#xD;
               -  Ejection Fraction &lt;35%&#xD;
&#xD;
               -  PR interval &gt; 200 msec on screening ECG or known heart block&#xD;
&#xD;
               -  History of bronchospastic disease&#xD;
&#xD;
               -  Gastric Bypass&#xD;
&#xD;
               -  Parkinson's&#xD;
&#xD;
               -  Rheumatoid Arthritis&#xD;
&#xD;
               -  Psoriatic Arthritis&#xD;
&#xD;
               -  Connective Tissue disease&#xD;
&#xD;
          -  Undergoing treatment with any medications that affect bone turnover, including the&#xD;
             following:&#xD;
&#xD;
               -  adrenocorticosteroids (oral for &gt; 3 months within the past year or sustained&#xD;
                  inhaled corticosteroid use)&#xD;
&#xD;
               -  anticonvulsant therapy for seizures (carbamazepine, phenobarbital, or phenytoin&#xD;
                  within the previous year) pharmacological doses of: thyroid hormone (causing&#xD;
                  decline of thyroid stimulating hormone below normal, i.e. &lt; 0.3 miU/L)&#xD;
                  bisphosphonates (within the past 3 yrs) denosumab, romosozumab, estrogen therapy&#xD;
                  or treatment with a selective estrogen receptor modulator, or&#xD;
                  teriparatide/abaloparatide (within the past year)&#xD;
&#xD;
               -  Current use of calcium channel blockers&#xD;
&#xD;
               -  Current use of digitalis glycosides&#xD;
&#xD;
               -  Current or within the past 3 months use of thiazide diuretics&#xD;
&#xD;
               -  Current or within the past 3 months use of beta blockers&#xD;
&#xD;
          -  Clinical history of osteoporotic fracture (vertebral, hip, distal forearm, humerus, or&#xD;
             pelvis), or any recent fracture within the past 6 months prior to screening (other&#xD;
             than fingers, toes and facial fractures, which are all acceptable)&#xD;
&#xD;
          -  Evidence of moderate/severe vertebral deformity based on DXA vertebral fracture&#xD;
             assessment at screening&#xD;
&#xD;
          -  Spine or femur neck T-score ≤ -2.5, or 1/3 radius T-score ≤ -3, as they may be&#xD;
             candidates for standard osteoporosis drugs&#xD;
&#xD;
          -  Patients with serum 25-hydroxyvitamin D levels of &lt; 20 ng/ml, in order to ensure&#xD;
             vitamin D sufficiency&#xD;
&#xD;
          -  Resting systolic blood pressure &lt; 120 mm Hg, heart rate &lt; 55 bpm (average of 3&#xD;
             readings after a 5-minute rest and one minute between readings with an automatic cuff)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sundeep Khosla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammie Volkman, RN</last_name>
    <phone>507-538-6023</phone>
    <email>volkman.tammie@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Tweed</last_name>
    <phone>507-255-6663</phone>
    <email>TWEED.AMANDA@MAYO.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Sundeep Khosla, M.D.</investigator_full_name>
    <investigator_title>Dr. Francis Chucker and Nathan Landow Research Professor Distinguished Mayo Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

